As if Biomarker Discovery Isn't Hard Enough: the Consequences of Poorly Characterized Reagents

February 4, 2014

Journal Article

As if Biomarker Discovery Isn't Hard Enough: the Consequences of Poorly Characterized Reagents

Abstract

The advent of high throughput omic technologies over the past two decades has driven a vast expansion in the search for clinical biomarkers, as manifested by the plethora of publications on biomarker discovery (over 8,600) listed on PubMed since 2000. Unfortunately, the same time period has seen a relative dearth of clinically validated biomarkers that have received FDA approval; only 10 new cancer biomarkers have been approved by the FDA in the same time period [1].

Revised: April 29, 2014 | Published: February 4, 2014

Citation

Rodland K.D. 2014. As if Biomarker Discovery Isn't Hard Enough: the Consequences of Poorly Characterized Reagents. Clinical Chemistry 60, no. 1:290-291. PNNL-SA-99249. doi:10.1373/clinchem.2013.216382